Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01554982 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis
A Phase 3 study, sponsored by Keryx Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT01554982 is a Phase 3 study that has completed, run by Keryx Biopharmaceuticals. The registered enrollment target is 168 participants.
The verdict
NCT01554982, a Phase 3 study, has completed, sponsored by Keryx Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.
Interventions
- DRUG ferric citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01554982
The ClinicalTrials.gov registry entry for NCT01554982 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keryx Biopharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ferric citrate is the first listed.
NCT01554982 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01554982 about?
NCT01554982 is a clinical study titled "A Long-Term Safety Extension Trial of Ferric Citrate in Patients With End-Stage Renal Disease (ESRD) on Dialysis". A long-term safety study of ferric citrate (KRX-0502) in renal failure patients who have completed study KRX-0502-304. Only patients who participated in the KRX-0502-304 trial may participate in this trial.
What is the current status of trial NCT01554982?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2012-08. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01554982?
The interventions under investigation include: ferric citrate (DRUG).
Who is sponsoring clinical trial NCT01554982?
This trial is sponsored by Keryx Biopharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.